Parkinson’s disease is a neurodegenerative disorder that is usually diagnosed in its late stage on the basis of clinical ...

A new fluid biomarker for Parkinson’s disease (PD) was developed, offering a high-accuracy biological classification, ...

Researchers from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) have applied AI-driven processes for detecting tertiary ...

Researchers have identified a key enzyme driving forms of Parkinson's disease, and have shown how blocking it restores normal ...

Parkinson’s disease (PD) is a progressive neurodegenerative disorder, that severely impacts motor and non-motor functions. Early detection and effective ...

In Alzheimer's, Parkinson's, and type 2 diabetes, harmful protein aggregates and deposits, known as amyloid plaques, develop.

ZyVersa CEO Stephen Glover said, “ZyVersa is developing Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases, with ...

About 15% of the world’s population — more than 1-billion people — are affected by neurological disorders, from commonly known diseases like Alzheimer’s and Parkinson’s to hundreds of lesser-known, ...

Researchers have identified a key enzyme driving forms of Parkinson’s, and have shown how blocking it restores normal ...

Recently, diagnostic tests for Parkinson’s disease have focused on elevated levels of the α-synuclein protein in cerebrospinal fluid (CSF) or mitochondrial DNA in the blood, both of which can vary ...

As a leader in biotechnological solutions, Creative Biolabs has always been committed to providing innovative products to the scientific research community. SHIRLEY, NY, UNITED STATES, April 23, 2025 ...

While a comprehensive cure-all to these neurological conditions is unlikely, scientists are making headway into understanding their fundamental characteristics with the hope of preventing or ...